HCW Biologics
HCWB
9 hedge funds and large institutions have $457K invested in HCW Biologics in 2025 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, reducing their positions, and 3 closing their positions.
434% more capital invested
Capital invested by funds: $85.5K → $457K (+$371K)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
13% more funds holding
Funds holding: 8 → 9 (+1)
0.71% more ownership
Funds ownership: 0.25% → 0.96% (+0.71%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$363K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$67.2K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$47.9K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.7K |
| 5 |
Citigroup
New York
|
+$1.36K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$37.7K |
| 2 |
FFO
Fortitude Family Office
Scottsdale,
Arizona
|
-$230 |
| 3 |
SS
SBI Securities
Tokyo,
Japan
|
-$26 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DS
1
DRW Securities
Chicago,
Illinois
| $309K | +$363K | +13,906 | New |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $57.1K | +$67.2K | +2,571 | New |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $40.7K | +$47.9K | +1,834 | New |
|
|
GSWM
4
Golden State Wealth Management
Santa Ana,
California
| $37K | – | – | – |
|
5
Wells Fargo
San Francisco,
California
| $6.29K | – | – | – |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $5.78K | +$5.7K | +218 | +519% |
|
|
7
Citigroup
New York
| $1.15K | +$1.36K | +52 | New |
|
8
Osaic Holdings
Scottsdale,
Arizona
| $96 | – | – | – |
|
9
Bank of America
Charlotte,
North Carolina
| $37 | – | – | – |
|
|
SS
10
SBI Securities
Tokyo,
Japan
| $4 | -$26 | -1 | Closed |
|
|
11
UBS Group
Zurich,
Switzerland
| – | -$37.7K | -1,586 | Closed |
|
|
FFO
12
Fortitude Family Office
Scottsdale,
Arizona
| – | -$230 | -10 | Closed |
|
HCWB Hedge Fund Activity: Q3 2025 in Review
9 of the 7,629 institutional investors tracked by Wall St. Rank reported a position in HCW Biologics (HCWB) for Q3 2025, worth a combined $457K — up 434% from $85.5K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new HCWB positions and 3 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was DRW Securities, opening a new position worth an estimated $363K. The largest seller was UBS Group, exiting entirely with an estimated $37.7K sold.
- 9 institutional investors held HCW Biologics (HCWB) as of Q3 2025, up from 8 in Q2 2025.
- Funds reported $457K of HCW Biologics stock for Q3 2025, up 434% quarter-over-quarter.
- 4 funds opened new HCW Biologics positions in Q3 2025 and 3 closed out, a net change of +1 holder.
- The largest HCW Biologics buyer in Q3 2025 was DRW Securities, an estimated $363K added.
- The largest HCW Biologics seller in Q3 2025 was UBS Group, an estimated $37.7K sold.
Based on aggregated 13F filings for Q3 2025.